Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Petros Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PTPI
Nasdaq
8731
https://www.petrospharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Petros Pharmaceuticals Inc
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
- Mar 19th, 2024 1:00 pm
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
- Feb 14th, 2024 2:15 pm
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
- Jan 24th, 2024 2:15 pm
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
- Jan 17th, 2024 2:00 pm
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
- Dec 12th, 2023 3:00 pm
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider
- Dec 12th, 2023 2:15 pm
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)
- Oct 30th, 2023 1:15 pm
Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA
- Oct 19th, 2023 1:00 pm
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label
- Oct 4th, 2023 1:00 pm
Petros Pharmaceuticals to Present at the LD Micro Main Event XVI
- Sep 28th, 2023 12:00 pm
Petros Pharmaceuticals Provides Letter to Shareholders
- Sep 11th, 2023 1:00 pm
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 8:05 pm
Petros Pharmaceuticals Announces Capital Raise of $15 Million
- Jul 13th, 2023 8:30 pm
Scroll